Trial Profile
Efficacy and safe of Ledipasvir/Sofosbuvir with Ribavirin in Patients who failed Daclatasvir/Asunaprevir with chronic hepatitis C-multicenter,pilot study-
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 May 2019
Price :
$35
*
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 22 Aug 2017 Status changed from active, no longer recruiting to completed.
- 28 Oct 2016 Status changed from not yet recruiting to active, no longer recruiting.
- 31 May 2016 New trial record